04_08 Metastatic Renal Cell Carcinoma

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

İçerik Talking About Tumors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Talking About Tumors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.

5M ago 24:16

MP3•Bölüm sayfası

1. Historical Approach (cytoreduction, IFN-a, sunitinib
2. Prognostic risk scores
3. Evidence for modern doublet regimens
4. Later line therapy

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545
Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675
Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044
Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714
Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501
Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126
Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716
Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090
Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.